Drug Trial Radar · NCT06751238
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 24, 2025
Primary completion
Oct 31, 2029
Study completion Mar 11, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Conditions
- Juvenile Psoriatic Arthritis
Interventions
SecukinumabBiological
Intravenous secukinumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration on Day 1Time frame: Pre-infusion and end of infusion (EOI) at Day 1
- Maximum concentration at steady-state (Cmax, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
- Minimum concentration at steady-state (Cmin, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
- Area under the concentration-time curve at steady-state (AUCtau, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
- Average concentration at steady-state (Cavg,ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Loma Linda University Health
Loma Linda, California · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Ann and Robert H Lurie Childs Hosp
Chicago, Illinois · Recruiting
Col Uni Med Center New York Presby
New York, New York · Recruiting
Levine Childrens Hospital
Charlotte, North Carolina · Recruiting
Cincinnati Childrens Hospital
Cincinnati, Ohio · Recruiting
Univ Hosp Cleveland Medical Center
Cleveland, Ohio · Recruiting
Legacy Emanuel Research Hosp Portland
Portland, Oregon · Recruiting
Childrens Hosp Pittsburgh UPMC
Pittsburgh, Pennsylvania · Recruiting
Texas Arthritis Center
El Paso, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.